A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients.
Phase of Trial: Phase III
Latest Information Update: 20 Jun 2011
At a glance
- Drugs Atenolol; Hydrochlorothiazide; Valsartan
- Indications Hypertension
- Focus Pharmacodynamics
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
- 27 Oct 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.